Aquatic Capital Management LLC Grows Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Aquatic Capital Management LLC lifted its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 128.7% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 27,081 shares of the biopharmaceutical company's stock after purchasing an additional 15,241 shares during the period. Aquatic Capital Management LLC's holdings in Regeneron Pharmaceuticals were worth $19,291,000 at the end of the most recent reporting period.

Several other hedge funds also recently bought and sold shares of REGN. OFI Invest Asset Management bought a new position in shares of Regeneron Pharmaceuticals during the 4th quarter valued at approximately $28,000. Rakuten Securities Inc. grew its position in Regeneron Pharmaceuticals by 62.5% in the 4th quarter. Rakuten Securities Inc. now owns 39 shares of the biopharmaceutical company's stock valued at $28,000 after acquiring an additional 15 shares during the last quarter. Avalon Trust Co bought a new position in Regeneron Pharmaceuticals in the 4th quarter valued at $36,000. Crowley Wealth Management Inc. purchased a new stake in shares of Regeneron Pharmaceuticals in the 4th quarter worth $36,000. Finally, Private Wealth Management Group LLC lifted its holdings in shares of Regeneron Pharmaceuticals by 260.0% in the 4th quarter. Private Wealth Management Group LLC now owns 54 shares of the biopharmaceutical company's stock worth $38,000 after buying an additional 39 shares during the period. Institutional investors own 83.31% of the company's stock.

Regeneron Pharmaceuticals Trading Down 2.9 %

Shares of REGN traded down $17.46 on Thursday, reaching $581.31. 556,533 shares of the company's stock were exchanged, compared to its average volume of 739,045. The company has a current ratio of 4.73, a quick ratio of 3.95 and a debt-to-equity ratio of 0.09. The stock has a market capitalization of $63.55 billion, a P/E ratio of 15.20, a price-to-earnings-growth ratio of 2.34 and a beta of 0.44. The business has a 50 day moving average price of $631.31 and a two-hundred day moving average price of $717.21. Regeneron Pharmaceuticals, Inc. has a 12 month low of $525.99 and a 12 month high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last posted its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $8.22 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $8.83 by ($0.61). The firm had revenue of $3.03 billion for the quarter, compared to the consensus estimate of $3.40 billion. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The firm's quarterly revenue was down 3.7% compared to the same quarter last year. During the same quarter in the previous year, the business posted $9.55 earnings per share. Research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, June 6th. Stockholders of record on Tuesday, May 20th will be issued a dividend of $0.88 per share. The ex-dividend date is Tuesday, May 20th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.61%. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is currently 8.96%.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on REGN shares. Cantor Fitzgerald assumed coverage on Regeneron Pharmaceuticals in a research note on Tuesday, April 22nd. They issued an "overweight" rating and a $695.00 price target for the company. Leerink Partnrs upgraded shares of Regeneron Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a report on Wednesday, February 5th. TD Cowen decreased their price objective on shares of Regeneron Pharmaceuticals from $1,230.00 to $1,030.00 and set a "buy" rating on the stock in a report on Tuesday, February 4th. The Goldman Sachs Group decreased their price objective on shares of Regeneron Pharmaceuticals from $917.00 to $804.00 and set a "buy" rating for the company in a research note on Wednesday. Finally, Canaccord Genuity Group raised shares of Regeneron Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a report on Tuesday, April 22nd. One analyst has rated the stock with a sell rating, four have given a hold rating, nineteen have given a buy rating and three have given a strong buy rating to the company's stock. According to data from MarketBeat.com, Regeneron Pharmaceuticals presently has an average rating of "Moderate Buy" and a consensus target price of $892.60.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.